Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 3,527 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (Placebo Control) Clear all
Terminated Phase 2 Interventional Results available

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

NCT03376477
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GM-CSF vaccine, Lenalidomide, Prevnar13, Placebo Prevnar13, Placebo GM-CSF Vaccine
Biological · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

NCT02469519
View directory record Official record
Conditions
Premature Birth
Interventions
Betamethasone - ACTIVE, Normal Saline - PLACEBO
Drug · Other
Lead sponsor
Pediatrix
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Increased IV Hydration on Nulliparous Women Undergoing an Induction of Labor

NCT02989571
View directory record Official record
Conditions
Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions
Intravenous normal saline administered at 250ml/hr, Intravenous normal saline administered at 125ml/hr
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

NCT03834493
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Enzalutamide, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 5:19 AM EDT
Recruiting Phase 4 Interventional

Low-Dose Ketamine Infusion During Burn Wound Care

NCT06506565
View directory record Official record
Conditions
Burn, Pain, Dissociation, Opioid
Interventions
Ketamine, 0.9% NaCl
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

NCT01523067
View directory record Official record
Conditions
Essential Hypertension
Interventions
Vasomera (PB1046), 0.9% Sodium Chloride
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional

Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

NCT05796765
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline
Biological · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
14
States / cities
La Mesa, California • Miami, Florida • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia

NCT01987219
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
Albuterol-sulphate, Ipratropium-bromide, placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 22, 2026, 5:19 AM EDT
Recruiting Phase 4 Interventional

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
145
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 5:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700
View directory record Official record
Conditions
Episodic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

NCT05698095
View directory record Official record
Conditions
Pharmacokinetics, Safety, Tolerability
Interventions
5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of TAP Block in Cesarean Section Patients

NCT03493828
View directory record Official record
Conditions
Pain Control
Interventions
TAP block using Bupivacaine 0.5%, TAP block using Bupivacaine 0.25%, TAP block using Normal Saline
Procedure
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

NCT02500121
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Placebo, Pembrolizumab
Other · Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis

NCT02799472
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165, Placebo, MTX, Folic (or folinic) acid
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
El Cajon, California • Fort Lauderdale, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of the Use of Botox on Acne

NCT00765375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Botulinum Neurotoxin Type A, Bacteriostatic saline
Drug
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Not applicable Interventional Results available

The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia

NCT01146457
View directory record Official record
Conditions
Labor Pain
Interventions
Morphine, Saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

NCT01300728
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
NewGam 10% IVIG, Placebo
Drug · Other
Lead sponsor
Sutter Health
Other
Eligibility
50 Years to 84 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Biology of Resilience

NCT01011465
View directory record Official record
Conditions
Oxytocin, Placebo
Interventions
intranasal oxytocin, Placebo, Social support, No Social Support
Drug · Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
22 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients

NCT01635101
View directory record Official record
Conditions
Acute Pain
Interventions
IV Acetaminophen, IV Control
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
1 Day to 2 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 22, 2026, 5:19 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

NCT03110952
View directory record Official record
Conditions
Dengue
Interventions
TDENV-PIV, TDENV-F17, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

NCT01014650
View directory record Official record
Conditions
Healthy
Interventions
GLYX-13, IV normal saline
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 22, 2026, 5:19 AM EDT
Active, not recruiting Not applicable Interventional

Stellate Ganglion Block for PTSD

NCT05169190
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Stellate Ganglion Block, Sham Stellate Ganglion Block
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Long Beach, California • Tampa, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

A Study to Compare the Effects of Different Sized Particles on Cells in the Nose

NCT01257191
View directory record Official record
Conditions
Hypersensitivity, Immediate, Atopic Hypersensitivity
Interventions
Carbon Black, Diesel Exhaust Particles, Fine Concentrated Ambient Particles, Ultrafine Concentrated Ambient Particles, Saline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 22, 2026, 5:19 AM EDT